topotecan has been researched along with Leukemia, Smoldering in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cripe, LD; Pennington, K; Stender, MJ; Stephens, A; Stoner, C; Vaena, DA; Walker, P; Yiannoutsos, CT; Young, C | 1 |
| Billmeier, J; Galili, N; Gohar, S; Lisak, L; Mumtaz, M; Pervaiz, H; Raza, A; Wahid, K | 1 |
| Estey, EH | 1 |
| Beran, M; Estey, E; Giles, FJ; Kantarjian, HM; Keating, M; Koller, CA; Kornblau, S; O'Brien, SM | 1 |
| Andreeff, M; Beran, M; Cortes, J; Estey, E; Giles, FJ; Hayes, K; Kantarjian, H; Keating, M; Koller, CA; Kornblau, S; O'Brien, S; Pierce, SR; Vey, N; Wong, GC | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; O'Brien, S; Pierce, SA; Thall, PF; Wang, X | 1 |
1 review(s) available for topotecan and Leukemia, Smoldering
| Article | Year |
|---|---|
New agents for the treatment of acute myelogenous leukemia: focus on topotecan and retinoids.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Humans; Leukemia, Myeloid, Acute; Retinoids; Topotecan | 1998 |
5 trial(s) available for topotecan and Leukemia, Smoldering
| Article | Year |
|---|---|
Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Drug Administration Schedule; Enzyme Inhibitors; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Topotecan; Treatment Outcome | 2004 |
Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Thalidomide; Time Factors; Topotecan; Treatment Outcome | 2006 |
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Chromosome Aberrations; Genes, ras; Humans; Infusions, Intravenous; Karyotyping; Leukemia, Myelomonocytic, Chronic; Middle Aged; Remission Induction; Survival Analysis; Topotecan; Treatment Outcome | 1998 |
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Prognosis; Remission Induction; Topotecan | 1999 |
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction; Survival Rate; Time Factors; Topotecan; Treatment Failure; Vidarabine | 2001 |